Litcius/Paper detail

Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor

R. Benjamin Free, Caroline A. Cuoco, Bing Xie, Yoon Namkung, Varun V. Prabhu, Blair K. A. Willette, Marilyn M. Day, Marta Sánchez‐Soto, J. Robert Lane, Stéphane A. Laporte, Lei Shi, Joshua E. Allen, David R. Sibley

2021Molecular Pharmacology40 citationsDOIOpen Access PDF

Topics & Concepts

Dopamine receptor D2Allosteric regulationDopaminePharmacologyChemistryAntagonistDopamine receptorReceptorBiochemistryBiologyNeuroscienceReceptor Mechanisms and SignalingPharmacological Receptor Mechanisms and EffectsNeuropeptides and Animal Physiology
Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor | Litcius